Skip to main content

SKINVISIBLE, INC.

corporate_fare Company Profile

SKINVISIBLE, INC.

SKVI·OTC·Life Sciences·CIK 0001085277

Skinvisible, Inc. is a pharmaceutical research and development (R&D) company that develops and patents an innovative polymer delivery system, Invisicare, and formulates over forty topical skin products. The company, incorporated in 1998, out-licenses these products globally. Skinvisible targets the estimated $80 billion global skincare and dermatology market, the $30 billion global over-the-counter market, and other healthcare/medical and consumer goods markets. The company is also exploring new opportunities in large medical markets outside of dermatology, such as obesity, where topical or transdermal solutions could be viable. With research and development complete on forty products and numerous technology and product patents issued, Skinvisible aims to monetize its investment. Its business model involves out-licensing its patented prescription and over-the-counter (OTC) products featuring Invisicare to established international manufacturers and marketers of brands, and maximizing profits from already out-licensed products. Invisicare is a patented polymer delivery system that enhances the delivery of active ingredients for topically applied skin care products. Its technology combines active ingredients with a delivery system to extend the product's duration on the skin. Invisicare is formulated to carry water insoluble and certain cationic active ingredients in water-based products without alcohol, silicones, waxes, or other organic solvents. Products using Invisicare have demonstrated the ability to bond active ingredients to the skin for up to four hours and longer.

SKINVISIBLE, INC. (OTC:SKVI) is a publicly traded company in the Life Sciences sector. Wiseek monitors SKVI SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • SKINVISIBLE Reports Worsening Financials, $1.8K Cash, and Persistent Going Concern Warning
  • SKINVISIBLE Faces Substantial Doubt on Going Concern Amidst Deepening Losses, Precarious Liquidity, and Material Weakness in Controls

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$20K
Net Income
-$1.06M
Op. Cash Flow
-$38.41K
Free Cash Flow
-$42.5K
Gross Profit
$20K
Operating Income
-$496.31K
Cash & Equivalents
$2.62K
Debt / Equity
0.00×
Net Margin
-53.20×
Shares Outstanding
5.4M sh
Source: 10-K · filed 2026-03-31 · accession 0001663577-26-000087
Browse all tickers starting with S →
$0.2126
52-week range · as of 2026-05-13 $0.055 – $0.90
Market cap
$1.15M
Volume
550 (0.2× avg)
3-mo avg 3K
Live data · 2026-06-14 03:55 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SKVI - Latest Insights

SKVI
May 13, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.191683
Real-time Price: $0.2126 info
Change: +$0.020917 (+11%) info
Market Cap: $1.149M info
SKVI
Mar 31, 2026, 4:31 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.23713
Real-time Price: $0.2126 info
Change: -$0.02453 (-10%) info
Market Cap: $1.149M info